ArticleJournal of translational medicine2025
Integrative analysis of bulk and single-cell gene expression profiles to identify bone marrow mesenchymal cell heterogeneity and prognostic significance in multiple myeloma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Single-Cell Sequencing and Proteomics to Unravel Stem Cell Heterogeneity: Implications for Precision Regenerative Medicine.Stem cell reviews and reports · 2026Review
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundMultiple myeloma is a hematologic malignancy characterized by complex interactions within the tumor microenvironment, where mesenchymal stem cells (MSCs) contribute significantly to disease progression, immune suppression, and drug resistance.
methodsThis study investigated the heterogeneity of MSCs in multiple myeloma using single-cell RNA sequencing (10X) and bulk transcriptomic data. Further analysis was performed by Seurat, SCENIC, CellChat. GSE4581 and GSE136337 were used as training set and validation set to construct a newly described prognostic model through COX and LASSO.
resultsBy analyzing bone marrow samples from healthy donors and multiple myeloma patients at different Revised International Staging System (R-ISS) stages, this study identified distinct MSC subpopulations, including osteogenic, angiogenic, immune regulatory, and multipotent clusters, each of which plays unique roles in the tumor microenvironment. Interestingly, we found a unique subclone with upregulated expression of high mobility group proteins, these MSC exert a strong regulatory effect, which was defined as "HMGhMSC".
conclusionsOur findings reveal that the proportion of osteogenic MSCs, which are crucial for bone health, decreases as the disease progresses, which is correlated with the bone lysis commonly observed in advanced multiple myeloma. Additionally, immune regulatory MSCs contribute to the formation of an immunosuppressive microenvironment, promoting tumor immune evasion. A prognostic model based on HMGhMSC subpopulations was developed, which demonstrated that these cells have significant potential as therapeutic targets for improving the prognosis and developing treatments for bone disease in multiple myeloma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.